223 related articles for article (PubMed ID: 2946712)
1. The rapid ovarian secretory response to pituitary stimulation by the gonadotropin-releasing hormone agonist nafarelin in sexual precocity.
Rosenfield RL; Garibaldi LR; Moll GW; Watson AC; Burstein S
J Clin Endocrinol Metab; 1986 Dec; 63(6):1386-9. PubMed ID: 2946712
[TBL] [Abstract][Full Text] [Related]
2. Maturation of the normal pituitary-testicular axis, as assessed by gonadotropin-releasing hormone agonist challenge.
Ghai K; Rosenfield RL
J Clin Endocrinol Metab; 1994 Jun; 78(6):1336-40. PubMed ID: 8200935
[TBL] [Abstract][Full Text] [Related]
3. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Rosenfield RL; Barnes RB; Ehrmann DA
J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
5. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
Garibaldi LR; Aceto T; Weber C; Pang S
J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
[TBL] [Abstract][Full Text] [Related]
6. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies.
Ehrmann DA; Rosenfield RL; Cuttler L; Burstein S; Cara JF; Levitsky LL
J Clin Endocrinol Metab; 1989 Nov; 69(5):963-7. PubMed ID: 2529266
[TBL] [Abstract][Full Text] [Related]
7. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study.
Rosenfield RL; Perovic N; Ehrmann DA; Barnes RB
J Clin Endocrinol Metab; 1996 Sep; 81(9):3408-11. PubMed ID: 8784105
[TBL] [Abstract][Full Text] [Related]
8. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
10. Maturation of gonadotropin and sex steroid responses to gonadotropin-releasing hormone agonist in males.
Cuttler L; Rosenfield RL; Ehrmann DA; Kreiter M; Burstein S; Cara JF; Levitsky LL
J Clin Endocrinol Metab; 1993 Feb; 76(2):362-6. PubMed ID: 8432780
[TBL] [Abstract][Full Text] [Related]
11. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
Monroe SE; Blumenfeld Z; Andreyko JL; Schriock E; Henzl MR; Jaffe RB
J Clin Endocrinol Metab; 1986 Dec; 63(6):1334-41. PubMed ID: 2946710
[TBL] [Abstract][Full Text] [Related]
13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
14. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins.
Apter D; Bützow TL; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1993 Apr; 76(4):940-9. PubMed ID: 8473410
[TBL] [Abstract][Full Text] [Related]
16. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
Andreyko JL; Monroe SE; Jaffe RB
J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
[TBL] [Abstract][Full Text] [Related]
18. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
19. Maturation of the hypothalamo-pituitary-ovarian axis in adolescent girls.
Lemarchand-Béraud T; Zufferey MM; Reymond M; Rey I
J Clin Endocrinol Metab; 1982 Feb; 54(2):241-6. PubMed ID: 6798063
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist analog (nafarelin): a useful diagnostic agent for the distinction of constitutional growth delay from hypogonadotropic hypogonadism.
Kletter GB; Rolfes-Curl A; Goodpasture JC; Solish SB; Scott L; Henzl MR; Beitins IZ
J Pediatr Endocrinol Metab; 1996; 9(1):9-19. PubMed ID: 8887129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
